CGTX Cognition Therapeutics, Inc.
$0.60
Cognition Therapeutics, Inc. (CGTX) Earnings News
Earnings press releases, previews and reviews for Cognition Therapeutics, Inc. (CGTX), newest first. Our most recent is review: Cognition Therapeutics Narrows Loss and Lands FDA Alignment on a Leaner DLB Phase 3, but the Pivotal Trial Is Still Unfunded.
Thursday
November 5, 2026
10:01 AM ET
Cognition Therapeutics Narrows Loss and Lands FDA Alignment on a Leaner DLB Phase 3, but the Pivotal Trial Is Still Unfunded
Earnings Whispers · Review
Thursday
November 5, 2026
6:00 AM ET
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
Tuesday
November 3, 2026
1:17 PM ET
Cognition Therapeutics Heads Into Q3 With a Wider Loss Expected and a Sub-Dollar Stock
Earnings Whispers · Preview
Monday
November 2, 2026
7:30 AM ET
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
Thursday
August 6, 2026
4:15 PM ET
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update